Nyxoah will be participating in the
Piper Sandler 32nd Annual Virtual Healthcare Conference.
Watch the pre-recorded fireside chat with Olivier Taelman, CEO of Nyxoah.

Back to press releases

Publication of transparency notifications

30 th Sep, 2020

   -   

Mont-Saint-Guibert, Belgium

In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA publishes the below information. It is to be noted that the below notifications already take into account the shares in Nyxoah SA that were subscribed in the offering and admitted to trading on the regulated market of Euronext Brussels on an "as-if-and-when issued and/or delivered" basis as of 18 September 2020 but that were only issued and delivered on the date of “closing” of the initial public offering of Nyxoah SA, i.e. 21 September 2020.
 

1. Jürgen Hambrecht

Jürgen Hambrecht has announced that, on 18 September 2020, he held 1,047,029 shares, representing 4,89% of the total number of voting rights (21,423,859).

The notification dated 24 September 2020 contains the following information:

  • Reason for the notification: holding of voting securities upon first admission to trading

  • Notification by: a person that notifies alone

  • Persons subject to the notification requirement: Jürgen Hambrecht

  • Transaction date: 18 September 2020

  • Threshold that is crossed: 3%

  • Denominator: 21,423,859

  • Notified details:

A) Voting rights

Previous notification

After the transaction

 

# of voting rights

# of voting rights

% of voting rights

Holders of voting rights

 

Linked to securities

Not linked to the securities

Linked to securities

Not linked

to the securities

Jürgen Hambrecht

 

1,047,029

 

4.89%

 
 

TOTAL

1,047,029

0

4.89%

0.00%

 

2. Together Partnership

Together Partnership has announced that, on 18 September 2020, it held 2,503,500 shares, representing 11,69% of the total number of voting rights (21,423,859).

The notification dated 24 September 2020 contains the following information:

  • Reason for the notification: Holding of voting securities upon first admission to trading

  • Notification by: a person that notifies alone

  • Persons subject to the notification requirement: Together Partnership: Uitbreidingsstraat 10-15, 2600 Antwerp

  • Transaction date: 18 September 2020

  • Threshold that is crossed: 10%

  • Denominator: 21,423,859

  • Notified details:

A) Voting rights

Previous notification

After the transaction

 

# of voting rights

# of voting rights

% of voting rights

Holders of voting rights

 

Linked to securities

Not linked to the securities

Linked to securities

Not linked

to the securities

Together Partnership

 

2,503,500

 

11.69%

 
 

TOTAL

2,503,500

0

11.69%

0.00%

 

3. Cochlear Limited and Cochlear Investments Pty Ltd

Cochlear Limited has announced that, on 18 September 2020, it held via its subsidiary Cochlear Investments Pty Ltd 3,947,617 shares, representing 18.43% of the total number of voting rights (21,423,859).

The notification dated 23 September 2020 contains the following information:

  • Reason for the notification: Holding of voting securities upon first admission to trading

  • Notification by: a parent undertaking or a controlling person

  • Persons subject to the notification requirement:

    1.  Cochlear Limited: 1 University Avenue, Macquarie University, NSW 2109 (Australia)

    2.   Cochlear Investments Pty Ltd: 1 University Avenue, Macquarie University, NSW 2109

      (Australia)

  • Transaction date: 18 September 2020

  • Threshold that is crossed: 15%

  • Denominator: 21,423,859

  • Notified details:

A) Voting rights

Previous notification

After the transaction

 

# of voting rights

# of voting rights

% of voting rights

Holders of voting rights

 

Linked to securities

Not linked to the securities

Linked to securities

Not linked

to the securities

Cochlear Limited

 

0

0

0.00%

0.00%

Cochlear Investments Pty Ltd

 

3,947,617

0

18.43%

0.00%

 

TOTAL

3,947,617

0

18.43%

0.00%

 

  • Chain of controlled undertakings through which the holding is effectively held: Cochlear Limited, a company which is listed on the Australian Securities Exchange and which has no controlling shareholder, owns 100% of the share capital of Cochlear Investments Pty Ltd.

 

4.Robert Taub

Robert Taub has announced that, on 18 September 2020, he held via Robelga SRL, Ronata and MINV SA 2,817,470 shares, representing 13.15% of the total number of voting rights (21,423,859).

The notification dated 28 September 2020 contains the following information:

  • Reason for the notification: Holding of voting securities upon first admission to trading

  • Notification by: a parent undertaking or a controlling person

  • Persons subject to the notification requirement:

    1. MINV SA: Avenue Blucher 3,1180 Uccle

    2.   Robelga SRL: Avenue Blucher 3,1180 Uccle

    3.   Ronata: Avenue Blucher 3,1180 Uccle

    4. Robert Taub

  • Transaction date: 18 September 2020

  • Threshold that is crossed: 10%

  • Denominator: 21,423,859

  • Notified details:

A) Voting rights

Previous notification

After the transaction

 

# of voting rights

# of voting rights

% of voting rights

Holders of

voting rights

 

Linked to securities

Not linked to the securities

Linked to securities

Not linked

to the securities

Robert Taub

 

2,121,47

 

9.90%

 

Robelga SRL

 

0

 

0.00%

 

Ronata

 

0

 

0.00%

 

MINV SA

 

696,000

 

3.25%

 
 

TOTAL

2,817,470

0

13.15%

0.00%

 

  • Chain of controlled undertakings through which the holding is effectively held: MINV SA is 100% owned by ROBELGA SRL, which is 100% owned by Ronata (a partnership (société simple) without legal personality). Robert Taub has 100% usufruct and Marita Taub, his wife, has 100% bare ownership of Ronata.
     

5. Gilde Healthcare Holding BV and Gilde Healthcare III Management BV

Gilde Healthcare Holding BV has announced that, on 18 September 2020, it held via Gilde Healthcare III Management BV 3,153,822 shares, representing 14,72% of the total number of voting rights (21,423,859).

The notification dated 21 September 2020 contains the following information:

  • Reason for the notification: Holding of voting securities upon first admission to trading

  • Notification by: a parent undertaking or a controlling person

  • Persons subject to the notification requirement:

    1. Gilde Healthcare Holding BV: Newtonlaan 91, 3584 BP Utrecht, the Netherlands

    2. Gilde Healthcare III Management BV: Newtonlaan 91, 3584 BP Utrecht, the Netherlands

  • Transaction date: 18 September 2020

  • Threshold that is crossed: 10%

  • Denominator: 21,423,859

  • Notified details:

A) Voting rights

Previous notification

After the transaction

 

# of voting rights

# of voting rights

% of voting rights

Holders of

voting rights

 

Linked to securities

Not linked to the securities

Linked to securities

Not linked

to the securities

Gilde Healthcare Holding BV

 

0

 

0.00%

 

Gilde Healthcare III Management BV

 

3,153,822

 

14.72%

 
 

TOTAL

3,153,822

0

14.72%

0.00%

 

  • Chain of controlled undertakings through which the holding is effectively held: Gilde Healthcare III Management BV is controlled by Gilde Healthcare Holding BV. Gilde Healthcare Holding BV is not a controlled entity.
  • Additional information: Cooperatieve Gilde Healthcare III Sub-Holding UA and Cooperatieve Gilde Healthcare III Sub-Holding 2 UA hold the shares in Nyxoah. Gilde Healthcare III Management BV is the management company of these 2 entities, that in the absence of specific instructions can exercise the voting rights at its discretion.

 

6. ResMed Inc.

Resmed Inc. has announced that, on 18 September 2020, it held 794,235 shares, representing 3,71% of the total number of voting rights (21,423,859).

The notification dated 28 September 2020 contains the following information:

  • Reason for the notification: holding of voting securities upon first admission to trading

  • Notification by: a person that notifies alone

  • Persons subject to the notification requirement:

  • Resmed Inc.: 9001 Spectrum Center Boulevard, San Diego, CA 92123 (United States)

  • Transaction date: 18 September 2020

  • Threshold that is crossed: 3%

  • Denominator: 21,423,859

  • Notified details:

A) Voting rights

Previous notification

After the transaction

 

# of voting rights

# of voting rights

% of voting rights

Holders of voting rights

 

Linked to securities

Not linked to the securities

Linked to securities

Not linked

to the securities

ResMed Inc

 

794,235

 

3.71%

 
 

TOTAL

794,235

0

3.71%

0,00%

 

* **

- ENDS - 

 

For further information, please contact:

Nyxoah
Rémi Renard, VP Therapy Development and Education
remi.renard@nyxoah.com
+32 472 12 64 40

For media enquiries, please contact:

Consilium Strategic Communications
Amber Fennell, Ashley Tapp, Lindsey Neville, Taiana De Ruyck Soares 
Nyxoah@consilium-comms.com
+44 (0)20 3709 5700


About Nyxoah

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services for sleep disordered breathing conditions. Nyxoah’s lead solution is the Genio® system, a CE-Mark validated, user-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk1 and comorbidities including cardiovascular diseases, depression and stroke.

Following successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in March 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system.

For more information, please visit www.nyxoah.com.

Caution – CE marked since 2019. Investigational device in the United States. Limited by federal law to investigational use.

1 Young T. et al: Sleep Disordered Breathing and Mortality: Eighteen-Year Follow-up of the Wisconsin Sleep Cohort, Sleep. 2008 Aug 1; 31(8): 1071–1078.

Discover Genio®

A sleep solution by Nyxoah 

Discover Genio®

All rights reserved © 2020 Nyxoah S.A. All content on this presentation, including the texts, trademarks, service marks, logos, illustrations, photos, graphics, design etc., are the property of Nyxoah SA. Nyxoah S.A. owns all rights with respect to any of their trademarks, service marks, logos, and copyrighted works appearing on this presentation. Patented and design protected technology. Device not for sale in U.S. The Genio® system by Nyxoah is intended to be used for patients who suffer from moderate to severe Obstructive Sleep Apnea (AHI of 15 to 65), have not tolerated, failed or refused PAP therapy and are not significantly overweight. Reviewed and approved: February 2020

bubble
bubble
bubble
bubble
bubble